Angiomammography and Neoadjuvant Chemotherapy

Save

Report Abuse

Description

The best prognostic factor following neoadjuvant chemotherapy is the pathological complete response (pCR). pCR is defined as the absence of invading cells in the breast and lymph nodes following neoadjuvant chemotherapy treatment. Since patients with pCR have a better prognosis than those without pCR, some studies have evaluated different methods to predict pCR early in treatment. Thus, patients who do not respond optimally to treatment could be identified early and changed treatment in order to maximize the chances of pCR and avoid the morbidity of poorly effective treatments. To do this, several modalities have been proposed, including MRI, mammography, ultrasound, positron emission tomography, elastography, and serial biopsies, but these techniques have shown predictive and sometimes expensive. Nevertheless, assessment of tumor response after cycle 2 has been suggested to be appropriate for the prediction of pCR.

The main objective of this study is to compare the performance of two diagnostic modalities, namely CESM and MRI, in the evaluation of the response of a malignant breast tumor to neoadjuvant chemotherapy and the prediction of pCR. The radiological response will also be compared to the clinical response.

Targeted Conditions

Study Overview

Start Date
January 3, 2018
Completion Date
June 30, 2025
Enrollment
100
Date Posted
June 2, 2022
Accepts Healthy Volunteers?
No
Gender
Female

Locations

Full Address
St-Sacrement Hospital
Quebec City, Quebec G1S4L8, Canada

Eligibility

Minimum Age (years)
18
Eligibility Criteria
Inclusion Criteria:

Female aged 18 and over
Histologically proven breast cancer by large gauge needle
No evidence of distant metastasis
Neoadjuvant chemotherapy with or without concomitant targeted therapy
Breast tumor initially measurable by clinical examination

Exclusion Criteria:

Refusal to perform the biopsy or surgery
Pregnant or possibly pregnant woman

Usual contraindication to contrast product

Significant kidney failure
Allergy to contrast medium
frank hyperthyroidism
Usual contraindications to MRI

Study Contact Info

Study Contact Name
Jean-Charles Hogue
Study Contact Phone

Contact Listings Owner Form

Angiomammography and Neoadjuvant Chemotherapy 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
NCTid (if applicable)
NCT05402930